The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Alleles for Multiple Sclerosis Identified by a Genomewide Study
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa073493 · Cited by 1,746
Advances in interleukin 2 receptor targeted treatment
Morris, J. C., & Waldmann, T. A. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.suppl_1.i109 · Cited by 131
Cited by
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Wuest, S. C., Edwan, J. H., Martin, J. F., Han, S., Perry, J. S. A., Cartagena, C. M., Matsuura, E., Maric, D., Waldmann, T. A., & Bielekova, B. (2011) · Nature Medicine · doi:10.1038/nm.2365 · Cited by 284
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Milo, R. (2014) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613504021 · Cited by 38
Innate lymphoid cell-derived cytokines in autoimmune diseases
Li, S., Yang, D., Peng, T., Wu, Y., Tian, Z., & Ni, B. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.05.001 · Cited by 19
Metadata
- Authors
- Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., Fong, A., & Rose, J. W.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 9
- Issue
- 4
- Pages
- 381-390
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2114942536
- Cited by
- 301
- References
- 2
- FWCI
- 27.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. https://app.cochat.ai/papers/10.1016/s1474-4422(10)70033-8
- The paper
- Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., Fong, A., & Rose, J. W. (2010). Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(10)70033-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
